Recent literature establishes that beta-hydroxybutyrate (BHB) is not merely a metabolic fuel, but a potent signaling molecule. By acting as an endogenous inhibitor of class I and IIa HDACs at physiological concentrations (2-5 mM Ki), BHB supplementation extended mean lifespan in C. elegans by approximately 20% [https://digitalcommons.usf.edu/bcm_facpub/8/]. This longevity effect requires HDACs hda-2 and hda-3 and is mediated by conserved stress-response pathways, including DAF-16/FOXO and SKN-1/Nrf2 [https://pmc.ncbi.nlm.nih.gov/articles/PMC4169858/].

However, a critical mechanistic paradox remains unresolved: How does BHB selectively activate SKN-1/Nrf2 without the reactive oxygen species (ROS) typically required to decouple it from its cytosolic repressor (Keap1/WDR-23)? Antioxidant treatments like N-acetylcysteine (NAC) fail to blunt BHB's longevity benefits, indicating a strictly ROS-independent pathway.

The Hypothesis

I hypothesize that BHB's specific longevity effects rely not on global, non-specific histone acetylation, but on a highly localized epigenetic modification: histone $\beta$-hydroxybutyrylation (Kbhb).

I propose that BHB acts synergistically as both an HDAC inhibitor and an active acyl-donor substrate. By inhibiting class I HDACs (hda-2/3)—which likely act as both deacetylases and de-hydroxybutyrylases—BHB drives the accumulation of specific Kbhb marks (e.g., H3K9bhb) at target promoters. Crucially, these Kbhb marks serve as direct epigenetic docking sites that recruit and anchor SKN-1/Nrf2 to chromatin, entirely bypassing the need for canonical ROS/Keap1 signaling.

Mechanistic Rationale

The prevailing model suggests BHB broadly increases chromatin accessibility by preventing deacetylation [https://pmc.ncbi.nlm.nih.gov/articles/PMC4414129/]. But broad accessibility does not explain target specificity.

Under my model, the deposition of H3K9bhb specifically at the promoter of targets like the short-chain dehydrogenase F55E10.6 recruits SKN-1. Upregulation of F55E10.6 subsequently shifts local TCA cycle fluxes, leading to the accumulation of succinate. This succinate competitively inhibits prolyl hydroxylases (PHDs) to stabilize HIF-1 [https://pmc.ncbi.nlm.nih.gov/articles/PMC4169858/].

By physically tethering SKN-1 activation to the metabolic state of the cell via Kbhb, BHB acts as a spatiotemporal bridge. This explains how BHB inhibits age-related intestinal stem cell hyperproliferation and DNA damage [https://pmc.ncbi.nlm.nih.gov/articles/PMC7278929/] without inducing the toxic, non-specific ROS bursts normally required for Nrf2 activation.

Falsifiability and Experimental Design

This hypothesis offers a clear, testable divergence from the "generic acetylation" model. It can be falsified through the following experiments:

1. ChIP-Seq Profiling: Compare H3K9ac versus H3K9bhb occupancy at the F55E10.6 promoter in BHB-treated C. elegans. If the hypothesis holds, we should observe preferential, localized Kbhb enrichment corresponding to SKN-1 binding sites.
2. Pharmacological Divergence (The NAC Test): Treat nematodes with a non-metabolizable, synthetic class I HDAC inhibitor (e.g., Vorinostat/SAHA) versus BHB. Because SAHA only induces acetylation and cannot act as a Kbhb substrate, any SKN-1 activation it triggers should be ROS-dependent and completely blocked by NAC. BHB-induced SKN-1 activation, driven by Kbhb docking, will remain NAC-resistant.
3. Isotope Tracing: Using 13C-labeled BHB, track direct carbon incorporation into histone Kbhb marks at target promoters. RNAi knockdown of HDACs hda-2 or hda-3 [https://pmc.ncbi.nlm.nih.gov/articles/PMC4169858/] should trap the 13C-Kbhb mark on the histones, proving these HDACs are the primary "erasers" of this specific longevity-promoting modification.

Understanding BHB through the lens of targeted Kbhb deposition rather than generic HDAC inhibition may finally resolve the controversy around the dosing of HDAC inhibitors in mammalian longevity and cancer therapeutics [https://www.oaepublish.com/articles/cdr.2024.103].